Silence Therapeutics’ (SLN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research report sent to investors on Thursday, Benzinga reports. The firm currently has a $75.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. Morgan Stanley reissued an overweight rating and set a $45.00 target price on shares of Silence Therapeutics in a research report on Monday, April 22nd. Chardan Capital reiterated a buy rating and set a $42.00 price objective on shares of Silence Therapeutics in a report on Friday, May 17th.

Silence Therapeutics Price Performance

SLN opened at $19.00 on Thursday. Silence Therapeutics has a 12 month low of $4.84 and a 12 month high of $27.72. The stock has a fifty day moving average price of $21.22 and a 200-day moving average price of $20.92.

Silence Therapeutics (NASDAQ:SLN) last announced its earnings results on Thursday, May 16th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.18. The business had revenue of $15.73 million during the quarter, compared to the consensus estimate of $4.53 million. Silence Therapeutics had a negative net margin of 131.44% and a negative return on equity of 79.90%. Analysts expect that Silence Therapeutics will post -1.52 earnings per share for the current year.

Institutional Trading of Silence Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC raised its stake in shares of Silence Therapeutics by 10.5% in the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock worth $151,000 after purchasing an additional 667 shares during the last quarter. Parkman Healthcare Partners LLC boosted its position in Silence Therapeutics by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,063 shares in the last quarter. Lynx1 Capital Management LP grew its holdings in Silence Therapeutics by 123.4% in the first quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock valued at $11,375,000 after purchasing an additional 290,855 shares during the period. Vivo Capital LLC purchased a new stake in shares of Silence Therapeutics in the fourth quarter valued at approximately $8,862,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Silence Therapeutics during the 1st quarter worth approximately $13,575,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.